Pharmafile Logo

Genomics England

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

Dendreon’s cancer vaccine wins EU approval

Provenge approved for use in prostate cancer three years after US recommendation

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Personalised understanding: oncology and orphan diseases

Improvements in our understanding of cancer are drawing the orphan drug and oncology worlds ever closer together

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links